Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

ABPI suspends Novo Nordisk’s membership for two years

The Association of the British Pharmaceutical Industry (ABPI) has suspended the membership of Novo Nordisk for two years due to serious breaches of its Code of Practice.

The action was taken by the ABPI Board following an investigation and appeals process conducted by the Prescription Medicines Code of Practice Authority (PMCPA) which found Novo Nordisk to be in breach of the ABPI Code of Practice, including Clause 2 which deals with actions “likely to bring discredit on, or reduce confidence in, the pharmaceutical industry”.


Having considered the case and requesting a further detailed audit of Novo Nordisk’s compliance processes, the ABPI Board decided to suspend Novo Nordisk from ABPI membership.

Susan Rienow, President-Elect, ABPI, said: “The ABPI Board has carefully considered the PMCPA’s case report into Novo Nordisk and the subsequent audit of their compliance procedures.

“The Board expressed significant concern about Novo Nordisk’s compliance activities and the very serious issues identified. As a result, the ABPI Board have taken the decision to suspend Novo Nordisk from ABPI membership.

“Such measures are never taken lightly, but will ensure a rapid return to industry compliance standards as set out in the ABPI Code of Practice”.

This is the eighth occasion in the past 40 years the ABPI board has issued such a significant sanction. As a result, while the company continues to be subject to the ABPI Code and the jurisdiction of the PMCPA, it will not be able to access the wider benefits of ABPI membership. This includes the removal of Novo Nordisk from all ABPI groups, including the ABPI Board, and access to any ABPI information and briefing.

In addition, the Board has stipulated a number of additional actions to demonstrate a rapid return to industry compliance standards. These include requiring the PMCPA to undertake further audits of Novo Nordisk’s compliance in late 2023 and 2024.

These audit reports will need to show clear, significant, and then sustained improvement to industry standards in order for the ABPI Board to consider allowing Novo Nordisk to resume full engagement with the ABPI at the end of the two-year suspension. The ABPI Board has reserved the right to take further decisions following the review of either of the re-audit reports.

The ABPI Board has also insisted that Novo Nordisk must submit a quarterly update to the ABPI Board giving the company’s views on the progress being made against its improvement plan.

More For You

Lung Cancer

Serplulimab helps immune cells recognise and destroy cancer cells more effectively.

iStock

Serplulimab gets MHRA approval for treating small cell lung cancer

The monoclonal antibody Serplulimab has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat adults with extensive-stage small cell lung cancer.

This cancer develops in the airways of the lungs and spreads fast within the lungs and other parts of the body.

Keep ReadingShow less
FCI scanner developed in Aberdeen aims to detect glioblastoma more safely than MRI scans

The Field Cycling Imaging scanner developed at the University of Aberdeen will provide more precise images than MRI scans

iStock

New scanner could improve brain tumour treatment

A new type of scanner shows promise in generating never-before-seen brain tumour images and is expected to help in treatment of glioblastoma patients.

The Field Cycling Imaging (FCI) scanner developed at the University of Aberdeen will provide more precise images than MRI scans.

Keep ReadingShow less
St James's University Hospital , NHS

Care Quality Commission downgraded the maternity and neonatal services at St James's University Hospital and Leeds General Infirmary.

Getty images

Two Leeds maternity units downgraded after inspection

The NHS regulator has downgraded two hospitals in Leeds to "inadequate" from "good" following an inspection.

The Care Quality Commission (CQC) said the maternity and neonatal services at Leeds General Infirmary (LGI) and St James' University Hospital of the Leeds Teaching Hospitals (LTH) NHS Trust posed "a significant risk" to women and babies.

Keep ReadingShow less
Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Primary care leaders join forces in effort to 'transform investment into primary care'

Community Pharmacy England (CPE) has teamed up with other national primary care bodies to urge the government to allocate more funds towards the sector.

In a joint statement released on the back of the government’s spending review, last week, the organisations welcomed the government’s continued determination to ‘shift care from hospitals to community and from sickness to prevention’ but warned that this would not be possible ‘without further investment in primary care’.

Keep ReadingShow less
Cancer patients warned against using weight-loss jabs

Macmillan Cancer Support said there is not enough evidence on how the weight-loss jabs might affect anti-cancer treatments.

iStock

Cancer patients warned against using weight-loss jabs

Cancer patients have been advised to consult their doctor before taking any weight-loss jabs.

Macmillan Cancer Support has issued this advisory following a surge in calls by cancer patients asking whether they can take fat loss jabs such as Wegovy and Mounjaro.

Keep ReadingShow less